Tempus AI Inc is a technology company... Show more
Tempus AI operates a two-sided platform that combines molecular diagnostics with a fast-growing data and applications segment. Its Diagnostics business performs genomic testing for patients and providers, while its Data and Applications arm licenses de-identified, outcome-linked datasets and AI tools to pharmaceutical companies and researchers. This structure creates a reinforcing "data flywheel," in which each new test and partnership expands the dataset that makes its models more valuable.
The company's competitive moat rests on scale and integration. It is connected with more than 5,500 hospitals and over 8,500 oncologists, giving it distribution and workflow access that is difficult to replicate. Management has also expanded beyond oncology into digital pathology, cardiology, and neuroscience, broadening the addressable market. Strategically, Tempus has deepened multi-year collaborations with major pharmaceutical partners, signaling a shift from transactional data licensing toward long-term, model-building relationships. Over the medium term, the company's ability to convert regulatory approvals into higher reimbursement and to scale its MRD testing franchise will be central to its market positioning.
The most immediate catalyst is the third-quarter 2026 earnings release on November 2, where investors will focus on revenue trajectory against full-year guidance of approximately $1.595 billion to $1.605 billion, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of roughly $65 million, and commentary on the Personalis acquisition, which is expected to close into 2027.
Regulatory milestones also loom large. FDA approval of the tumor-only xT companion diagnostic is expected to lift average selling prices by an estimated $200 per test, translating to roughly $85 million in annual revenue uplift beginning in 2027. A potential approval of the xF liquid biopsy assay in the latter half of 2027 could add a further estimated $550 million in annual selling-price uplift, according to management commentary. Internationally, the xR RNA assay recently received European Union IVDR certification, opening additional geographic opportunity.
Analyst activity has turned more optimistic heading into year-end. Several firms raised price targets in October 2026, including Canaccord Genuity ($80 to $95), Guggenheim ($65 to $92), Bank of America ($52 to $75), and J.P. Morgan ($45 to $70). Consensus coverage now averages a "Buy" rating with a mean 12-month price target near $75, though the dispersion from roughly $35 to $100 underscores continued debate over valuation and execution risk.
Tempus AI's trajectory is closely tied to healthcare technology adoption and the pharmaceutical research-and-development cycle. Rising adoption of comprehensive genomic profiling and precision oncology supports volume growth in its core diagnostics business, while demand for real-world data among drug developers underpins the higher-margin data segment.
Macroeconomic factors matter indirectly. Interest rates influence the valuation of growth-stage, cash-flow-negative companies and the cost of capital for acquisition financing. The company has already refinanced debt through a $460 million convertible note offering, which management says will reduce annual interest expense by more than $30 million. Inflation and labor costs affect laboratory operating expenses, while reimbursement policy and payer willingness to cover AI-driven diagnostic algorithms represent a structural regulatory variable. Finally, geopolitical and supply-chain dynamics can influence sequencing costs and pharmaceutical research budgets, though the company's core demand drivers remain domestic clinical and pharmaceutical adoption trends.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF (exchange-traded fund), or other asset may trend bullish, bearish, or sideways over the next week or month. Designed to surface developing trends, evaluate possible breakouts or reversals, and support exploration across a broad range of tradable instruments, the platform offers searchable prediction categories, historical context, and alert-oriented functionality. For investors monitoring a dynamic name like Tempus AI, the engine provides a neutral, data-driven complement to fundamental analysis.
Looking toward 2026 and beyond, Tempus AI's outlook centers on several structural themes. First, the transition from high-growth investment toward scaled profitability remains the central financial narrative, with management targeting positive adjusted EBITDA and improved cash generation as revenue scales. Second, MRD testing represents a potentially large market-expansion opportunity, though commercialization is being deliberately paced to align with reimbursement economics.
Margin sustainability will depend on laboratory automation, favorable pricing from regulatory approvals, and the mix shift toward higher-margin data licensing. Technology transitions, including the deployment of foundation models built with pharmaceutical partners and the launch of AI pathology tools such as Paige Predict, could broaden the company's product ecosystem beyond its historical oncology core. Competitive threats from established diagnostics firms and large technology companies entering healthcare AI warrant monitoring.
Capital allocation priorities, including the pending Personalis transaction and debt refinancing, will shape the balance sheet over the coming years. Consensus expectations currently model revenue growth in the mid-teens to mid-twenties percentage range annually, with profitability anticipated to inflect over the next several years. These assumptions, rather than any single quarterly result, are likely to define how long-term sentiment around the stock evolves.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TEM has been loosely correlated with SDGR. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if TEM jumps, then SDGR could also see price increases.
| Ticker / NAME | Correlation To TEM | 1D Price Change % | ||
|---|---|---|---|---|
| TEM | 100% | -6.30% | ||
| SDGR - TEM | 62% Loosely correlated | -3.16% | ||
| TXG - TEM | 52% Loosely correlated | +0.54% | ||
| SOPH - TEM | 47% Loosely correlated | -10.58% | ||
| GEHC - TEM | 40% Loosely correlated | -2.12% | ||
| CERT - TEM | 36% Loosely correlated | -4.47% | ||
More | ||||
| Ticker / NAME | Correlation To TEM | 1D Price Change % |
|---|---|---|
| TEM | 100% | -6.30% |
| Services to the Health Industry industry (41 stocks) | 19% Poorly correlated | -4.19% |
| Health Services industry (238 stocks) | 6% Poorly correlated | -3.34% |
Industry ServicestotheHealthIndustry
TEM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 13, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 23 instances where the indicator turned negative. In 21 of the 23 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TEM as a result. In 29 of 37 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
TEM moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TEM crossed bearishly below the 50-day moving average on November 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for TEM entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +19.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in 117 of 132 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
TEM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (31.032) is slightly higher than the industry average of (4.523). TEM has a moderately low P/E Ratio (-52.812) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.105).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.